Enhancing Chemotherapy Sensitivity in Canine Tumors
Author Information
Author(s): Bart Spee, Martijn D. Jonkers, Brigitte Arends, Gerard R. Rutteman, Jan Rothuizen, Louis C. Penning
Primary Institution: Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University
Hypothesis
Does RNA interference against XIAP increase the sensitivity of canine tumor cell-lines to TRAIL and doxorubicin?
Conclusion
XIAP directed siRNA's significantly enhance the sensitivity of canine tumor cell-lines to TRAIL and doxorubicin.
Supporting Evidence
- All XIAP siRNA treated cell-lines showed over 80% mRNA down-regulation.
- BDE cells showed a 14-fold increase in sensitivity to TRAIL after XIAP depletion.
- Doxorubicin treatment increased sensitivity in BDE cells by more than eight-fold.
Takeaway
Scientists found a way to make cancer cells in dogs more sensitive to treatments by using a special technique that reduces a protein that protects the cells from dying.
Methodology
The study used small interfering RNA (siRNA) to target XIAP in three canine tumor cell-lines and measured cell viability after treatment with TRAIL and doxorubicin.
Limitations
The study was conducted in vitro, and the results may not directly translate to in vivo applications.
Participant Demographics
Canine tumor cell-lines derived from bile-duct epithelia, mammary carcinoma, and osteosarcoma.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website